Earlier that day, the company will announce its financial guidance for 2019. At the investment community meeting, Lilly leadership will further detail the 2019 financial guidance and discuss progress towards the company's strategic goals, as well as the commercial performance of recently launched medicines. A substantial portion of the meeting will then focus on Lilly's research and development opportunities in the areas of oncology, pain, neurodegeneration, immunology and diabetes.
SOURCE Eli Lilly and Company
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.

